Innovent Biologics (HKG:1801) recorded a total product revenue of 2 billion yuan or more in the fourth quarter of 2024, up at least 25% from a year prior, a Thursday bourse filing said.
In full-year 2024, product revenue grew by at least 40% to 8.2 billion yuan.
The drug company attributed the rise in revenue mainly to its leading position in the oncology niche, fast growth of major products, and the strong ramp-up momentum of new products.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。